DNAprint Genomics (DNAG)

[worktoplay]

Arch...Doubtful, but we don't have to work directly with Amgen to develop the classifier. We're working with samples, or will be, with Beth Isreal/Harvard. EPO is EPO, at least the older version is and there are plenty of patient samples available to develop a classifer.

But speaking of the recent problems J&J and AMGEN are having and the need to add a warning label to their EPO products, it makes this old post somewhat prophetic wouldn't you say?

http://investorshub.com/boards/read_msg.asp?message_id=6002794

Perhaps the FDA has been reading the iHub Board! LOL

Later,
W2P